FluoGuide is trading 5.9% down at SEK 31.70 now; the catalyst for the move is unclear. - On October 5, FluoGuide announced that the first patient had enrolled in its U.S. Phase 2 FG001 trial for newly diagnosed high-grade glioma. - This is a clinical milestone, but available reporting does not establish that the announcement caused the indicated decline. - The market was closed at the stated time, so SEK 31.70 is not a confirmed October 6 closing price.